Round and round with Angiomax

Following last week's events with Angiomax, with the USPTO playing hardball, it appears we will have a reprise. From Reuters:

[Medicines Co] filed the complaint on March 25 against the PTO, the U.S. Food and Drug Administration and the U.S. Department of Health and Human Services.

Last week, the PTO again denied a patent extension for the drug, three days after a Virginia district court asked the patent office to reconsider an earlier denial for extension.

See prior IPBiz post:

http://ipbiz.blogspot.com/2010/03/not-looking-good-for-medicines-company.html